Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2012-07-20 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2012
Regulatory Filings
2012-07-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It references exhibits including a Financial Report for Q2 2012 and an Interim Financial Report. The document length is only 1494 characters, which is quite short and does not contain substantive financial data itself but rather indicates the submission of financial reports. According to the MENU VS MEAL RULE, such a short document that announces or submits reports without containing the full report content should be classified as a Regulatory Filing (RNS).
2012-07-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing a positive opinion from the European Medicines Agency's CHMP for a drug (Seebri Breezhaler) to treat COPD. It includes clinical trial results, product information, and forward-looking statements. There are no financial statements or detailed financial performance data presented. The document is primarily a regulatory announcement and press release about a product approval milestone rather than a financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, nor a Management Discussion and Analysis. It is also not a proxy, voting result, or governance document. Given the nature of the filing (Form 6-K) and the content (media release about regulatory approval and clinical trial results), the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is substantial (15,000 characters), so it is not a mere report publication announcement. Confidence is high due to clear identification of the document type and content.
2012-06-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing the CHMP recommendation for the drug Afinitor for EU approval, including clinical trial results and regulatory status updates. It is not a full financial report, audit report, or earnings release. It is a regulatory announcement about a drug approval milestone and related clinical data, typical of a regulatory filing. The document length is 15,000 characters, and it contains detailed information but is not a financial report or management discussion. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2012-06-22 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG to the SEC responding to comments on their previously filed Form 20-F for the fiscal year ended December 31, 2011. It addresses specific SEC requests about disclosures to be included in future periodic reports, particularly the 2012 Form 20-F. The letter includes detailed responses about operating results and financial statement notes but does not itself contain the full annual report or financial statements. It is a correspondence related to regulatory review and compliance rather than the report itself. The document length is moderate (5574 characters), and it is clearly a regulatory response letter, not the actual Form 20-F or Annual Report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such correspondence and compliance documents.
2012-06-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release detailing long-term clinical trial results and safety data for the drug Gilenya, including study data and references to presentations at medical conferences. It is not a full financial report, audit report, or earnings release. It is a regulatory filing providing material information to the SEC and investors but does not contain financial statements or detailed financial analysis. The document length is about 15,000 characters, which is substantial but the content is primarily a press release with clinical data and corporate information. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2012-06-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.